Transplantation: time to rethink immunosuppression by mTOR inhibitors?
Several surprising findings indicate that pharmacological blocking of the multifunctional enzyme mTor fosters distinct differentiation programs in different immunocompetent cells. These data might lead to a striking change in our view of the role that mTor inhibition should have in immunosuppressive therapy for allogeneic transplant recipients.
Marcus D
MD
Säemann
Giuseppe
G
Remuzzi
D000068338:Everolimus; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016377:Organ Transplantation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011494:Protein Kinases / Q000502:physiology; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases
D007166:Immunosuppressive Agents; D047428:Protein Kinase Inhibitors; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus